359 related articles for article (PubMed ID: 31656201)
21. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
22. RAD51AP1 promotes progression of ovarian cancer via TGF-β/Smad signalling pathway.
Zhao H; Gao Y; Chen Q; Li J; Ren M; Zhao X; Yue W
J Cell Mol Med; 2021 Feb; 25(4):1927-1938. PubMed ID: 33314567
[TBL] [Abstract][Full Text] [Related]
23. Min-redundancy and max-relevance multi-view feature selection for predicting ovarian cancer survival using multi-omics data.
El-Manzalawy Y; Hsieh TY; Shivakumar M; Kim D; Honavar V
BMC Med Genomics; 2018 Sep; 11(Suppl 3):71. PubMed ID: 30255801
[TBL] [Abstract][Full Text] [Related]
24. TET3 regulates DNA hydroxymethylation of neuroprotective genes following focal ischemia.
Morris-Blanco KC; Chokkalla AK; Bertogliat MJ; Vemuganti R
J Cereb Blood Flow Metab; 2021 Mar; 41(3):590-603. PubMed ID: 32380888
[TBL] [Abstract][Full Text] [Related]
25. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF
BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491
[TBL] [Abstract][Full Text] [Related]
26. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
27. Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer.
Xin B; Ji KQ; Liu YS; Zhao XD
J Ovarian Res; 2019 Aug; 12(1):75. PubMed ID: 31399054
[TBL] [Abstract][Full Text] [Related]
28. Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival.
Zhou F; Tao G; Chen X; Xie W; Liu M; Cao X
Clin Chem Lab Med; 2014 May; 52(5):735-42. PubMed ID: 24327526
[TBL] [Abstract][Full Text] [Related]
29. SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer.
Sun T; Bi F; Liu Z; Yang Q
Aging (Albany NY); 2020 Jul; 12(13):13281-13296. PubMed ID: 32647070
[TBL] [Abstract][Full Text] [Related]
30. Prognostic values of S100 family members in ovarian cancer patients.
Bai Y; Li LD; Li J; Lu X
BMC Cancer; 2018 Dec; 18(1):1256. PubMed ID: 30558666
[TBL] [Abstract][Full Text] [Related]
31. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
[TBL] [Abstract][Full Text] [Related]
32. PSMD8 can serve as potential biomarker and therapeutic target of the PSMD family in ovarian cancer: based on bioinformatics analysis and in vitro validation.
Li X; Li X; Hu Y; Liu O; Wang Y; Li S; Yang Q; Lin B
BMC Cancer; 2023 Jun; 23(1):573. PubMed ID: 37349676
[TBL] [Abstract][Full Text] [Related]
33. Prognostic roles of Notch receptor mRNA expression in human ovarian cancer.
Chen C; Wang X; Huang S; Wang L; Han L; Yu S
Oncotarget; 2017 May; 8(20):32731-32740. PubMed ID: 28415574
[TBL] [Abstract][Full Text] [Related]
34. Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis.
Xu Z; Zhou Y; Cao Y; Dinh TL; Wan J; Zhao M
Med Oncol; 2016 Nov; 33(11):130. PubMed ID: 27757782
[TBL] [Abstract][Full Text] [Related]
35. Phosphorylation of Tet3 by cdk5 is critical for robust activation of BRN2 during neuronal differentiation.
Rao VK; Swarnaseetha A; Tham GH; Lin WQ; Han BB; Benoukraf T; Xu GL; Ong CT
Nucleic Acids Res; 2020 Feb; 48(3):1225-1238. PubMed ID: 31807777
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic biomarkers in epithelial ovarian cancer.
Gloss BS; Samimi G
Cancer Lett; 2014 Jan; 342(2):257-63. PubMed ID: 22245949
[TBL] [Abstract][Full Text] [Related]
37. Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel.
Cicek MS; Koestler DC; Fridley BL; Kalli KR; Armasu SM; Larson MC; Wang C; Winham SJ; Vierkant RA; Rider DN; Block MS; Klotzle B; Konecny G; Winterhoff BJ; Hamidi H; Shridhar V; Fan JB; Visscher DW; Olson JE; Hartmann LC; Bibikova M; Chien J; Cunningham JM; Goode EL
Hum Mol Genet; 2013 Aug; 22(15):3038-47. PubMed ID: 23571109
[TBL] [Abstract][Full Text] [Related]
38. Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis.
Feng H; Gu ZY; Li Q; Liu QH; Yang XY; Zhang JJ
J Ovarian Res; 2019 Apr; 12(1):35. PubMed ID: 31010415
[TBL] [Abstract][Full Text] [Related]
39. Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer.
Tabassum A; Samdani MN; Dhali TC; Alam R; Ahammad F; Samad A; Karpiński TM
J Mol Med (Berl); 2021 Sep; 99(9):1293-1309. PubMed ID: 34047812
[TBL] [Abstract][Full Text] [Related]
40. A prognostic 11 genes expression model for ovarian cancer.
Men CD; Liu QN; Ren Q
J Cell Biochem; 2018 Feb; 119(2):1971-1978. PubMed ID: 28817186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
